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Ara A. Chrissian, MD,* Javier Diaz-Mendoza, MD,†‡
and Michael J. Simoff, MD†

Background: Nonsurgical patients with complex post-

intubation tracheal stenosis (PITS) and tracheostomyassociated tracheal stenosis (PTTS) often require airway
stenting. However, the optimal approach is unknown.
Identifying patients at higher risk for restenosis after
stent removal may allow the treating physician to individualize the vigilance and duration of airway stenting,
and help optimize outcomes.
Methods: This was a single-center retrospective analysis

of prospectively collected data on all patients with
complex PITS and/or PTTS treated with protocolized
bronchoscopic airway stenting over a consecutive
16-year period. The primary outcome analyzed was
restenosis rate at 1 year after stent removal. Predictors
for restenosis and factors inﬂuencing risk for death
during stent therapy were also assessed.
Results: Of the 181 subjects treated with silicone airway

stenting, 128 were available for analysis of the primary
outcome. Restenosis by 1 year after stent removal occurred
in 58%. Independent predictors for restenosis were coexisting diabetes [odd ratio (OR) = 3.10, 95% conﬁdence
interval (CI) = 1.04-9.24; P = 0.04], morbid obesity (OR =
3.13, 95% CI = 1.20-8.17; P = 0.02), and occurrence of
stent-associated complications requiring bronchoscopic
management (OR = 2.13, 95% CI = 1.12-4.03; P = 0.02).
The overall mortality during the initial stenting period was
14%, and a silicone Y-stent was associated with a higher
risk of death (OR = 3.58, 95% CI = 1.40-9.14; P = 0.008).
Conclusion: Tracheal restenosis after silicone stent therapy

for complex PITS and PTTS is common and more likely
to occur in patients with diabetes, morbid obesity, and
frequent stent-associated complications. Mortality risk
during stent therapy is not negligible, and a Y-stent should
be utilized only after careful consideration. These ﬁndings
may be incorporated into the approach to bronchoscopic
airway stenting in these patients.
Received for publication January 24, 2022; accepted May 17, 2022.
From the *Division of Pulmonary, Critical Care, Hyperbaric, Allergy,
and Sleep Medicine, Loma Linda University, Loma Linda, CA;
†Division of Pulmonary and Critical Care, Interventional Pulmonology Section, Henry Ford Hospital; and ‡Department of Internal
Medicine, Wayne State University, Detroit, MI.
Disclosure: There is no conﬂict of interest or other disclosures.
Reprints: Ara A. Chrissian, MD, Loma Linda University Medical
Center, 11234 Anderson Street, MC, Room 1516-D, Loma Linda,
CA 92354 (e-mail: achrissian@llu.edu).
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
DOI: 10.1097/LBR.0000000000000878

J Bronchol Intervent Pulmonol



Key Words: tracheal stenosis, airway stent, bronchoscopy,
tracheostomy, intubation
(J Bronchol Intervent Pulmonol 2022;00:000–000)

N

onmalignant tracheal stenosis is a relatively
rare yet debilitating and life-threatening
disease resulting from local injury and ischemia of
the airway wall. Endotracheal intubation [postintubation tracheal stenosis (PITS)] or placement
of a tracheostomy tube [post-tracheostomy tracheal stenosis (PTTS)] is often implicated. The
type and extent of the stenosis may be related to
the severity of insult, loss of cartilaginous integrity,
and underlying disease. A complex lesion is often
described as involving the full thickness of the
tracheal wall, measuring > 1 cm in length, or
exhibiting associated malacia.1,2 The deﬁnitive
treatment for complex tracheal stenosis is surgical
resection and tracheal reconstruction.3
Unfortunately, comorbid conditions in
patients with complex PITS/PTTS often preclude
surgical intervention. Bronchoscopic approaches
including airway stenting can be offered to individuals with limited options.2,4–10 Stenting aims to
stabilize and protect the diseased tracheal segment
while appropriate re-epithelialization and remodeling occurs. In a proportion of patients, the
stent may be removed allowing for long-term
airway stability, while in others recurrent narrowing necessitates re-intervention. Stent-related
complications include migration, airway obstruction and infection.11,12 These may interfere
with healing and expose the patient to additional
risk, including death.13 The heterogeneity and
relative paucity of the available literature studying
this patient population prevents reliable conclusions on predictors of initial stent therapy
success.
The primary purpose of this study was to
analyze the rate of tracheal restenosis after airway stent therapy in patients with complex PITS
and PTTS. Secondary goals were to identify
predictors of restenosis and predictors of death
during the initial stenting period. The sample
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source is a referral center that manages tracheal
stenosis not amenable to surgical correction. It
has a long-standing protocolized approach to
these patients, including indications for stenting,
scheduled bronchoscopic surveillance, duration
of therapy, and management of complications.
Consequently, the study database offers a valuable tool for assessing the utility of bronchoscopic management of complex PITS and PTTS
treated with airway stenting.
METHODS
Design

This was a retrospective analysis of prospectively collected data on all patients with
PITS and PTTS treated with airway stenting over
a consecutive 16-year period. The utilized database catalogs all bronchoscopic interventions by
multiple patient, procedure, and outcome-related
characteristics. The study hospital’s Institutional
Review Board provided its approval (#11450).
Data Collection

All patient, procedural, and outcome variables
were predeﬁned and a data extraction form was
created a priori. All data extraction and primary
analysis was performed by investigators not involved
in any of the procedures performed during the study
period. Each subject’s medical record was reviewed
in detail and compared with the existing prospective
database to ensure accuracy. Relevant missing data
points were added as needed, if available.
Outcomes

The primary outcome was tracheal restenosis
at 1 year after stent removal. Restenosis was
deﬁnitively diagnosed and characterized by
bronchoscopy, and deﬁned as a re-narrowing of
the airway requiring any intervention. As secondary outcomes, we analyzed predictors of restenosis after stent removal, and predictors of death
during the initial stenting period.
Patient Assessment for Airway Stenting

Airway stenting for PITS/PTTS was considered for a clinically signiﬁcant complex lesion or for
a simple lesion that recurred more than once
despite conservative measures. We deﬁned a
stenosis as clinically signiﬁcant if there was more
than 50% cross-sectional obstruction or if there was
dyspnea, regardless of extent of endoluminal compromise. Simple lesions were those without any
complex features: they were <1 cm in length, had
only mucosal involvement and no associated
malacia.1,2 Conservative measures used to treat
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simple stenoses included LASER-assisted mechanical dilation (LAMD) using either a rigid bronchoscope or airway balloon, with or without
mucosal application of steroid or mitomycin-C.
For all cases, airway stenting was offered after
evaluating the potential for surgical reconstruction
or tracheostomy tube placement/revision. This
assessment was based on disease-speciﬁc, anatomic,
comorbid, and patient-centered factors.
Airway Stenting Protocol

Only silicone stents were used, and in all cases
were deployed using rigid bronchoscopy. The type
and dimensions of the initial prosthesis was at the
discretion of the treating physician and was one of
a straight silicone stent (Bryan Corp or EndoxaneNovatech; Aubagne, France), a Y-shaped silicone
stent (Bryan Corp or Endoxane-Novatech;
Aubagne) or a Montgomery T-tube (Hood Laboratories; Pembroke, MA). Supplemental LAMD
was performed as indicated. The type of LASER
used was one of neodymium-doped yttrium aluminum garnet (Nd:YAG), potassium titanyl
phosphate, or Holmium. If LAMD was performed
at the time of stent placement, mucosal therapy
with steroid or mitomycin-C was applied per
discretion of the treating physician. After stent
insertion, each patient was given a stent clearance regimen and scheduled for surveillance
bronchoscopy at 1 month and 3 months poststent
placement. Additional bronchoscopies to manage
complications were performed as needed.
The goal of stent therapy was to promote and
allow time for airway remodeling. During the ﬁrst
8 years of the study period, the stent was removed
after maintaining 6 months of a stable airway,
deﬁned as a continuously stent-covered lesion.
During the latter 8 years, the stent was removed
after 4 months of a stable airway. This change in
practice was because of apparent similar outcomes
between the 2 approaches found during an internal
quality review (unpublished data). Reasons for stent
removal before completion of protocolized indwelling time included recurrent complications or patient
noncompliance. After stent removal, all patients
were evaluated with bronchoscopy 1 week and then
1-month postremoval. They were then followed at 3,
6, and 12 months using a combination of clinical
assessment, spirometry, computed tomography
scanning, and bronchoscopy as needed.
Statistical Analysis

Statistical analysis was performed using SPSS
software (IBM SPSS Statistics, Chicago, IL) and R
Cran version 3.5.1 (R Core Team, 2019). Simple
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bivariate analyses were conducted to evaluate differences between restenosis or death status (the
Pearson χ2 or the Fisher exact tests for categorical
variables and 2 sample t test or Mann-Whitney U
test for continuous variables). Multivariate logistic
regression analysis was used to determine predictors of restenosis and death. Variables chosen
for these models were based on clinical relevance
and/or suggestion of signiﬁcant group differences
during bivariate analysis.
RESULTS

A total of 346 patients treated for PITS or
PTTS over the consecutive 16-year study period
were identiﬁed. Of these, 198 were managed with
airway stenting, with 181 having follow-up for at
least 6 months after stent placement or until
removal (Fig. 1). Acuity was high, with 47% of
subjects hospitalized at time of diagnosis. A large
majority (94%) of stented stenoses were complex,
48% percent had severe (Cotton-Myer ≥ 3)

Tracheal Restenosis Postairway Stenting

tracheal narrowing, and 40% were longer than
2 cm. Most lesions (84%) were located in the
proximal trachea, and 64% were associated with
current or past tracheostomy (PTTS).
A straight silicone stent was the most common initial stent placed (69%). In 45 subjects
(25%), a silicone Y-stent was chosen for initial
intervention. At least 1 delayed stent-associated
complication occurred in 69% of subjects
(Table 1). Granulation (39%) and migration
(34%) were most common. To manage these, 2.5
bronchoscopies in addition to those performed
for routine stent surveillance were required.
Overall, excluding the procedures required
for initial stent placement and ﬁnal removal,
patients received an average of 3.4 bronchoscopies during their initial stenting period. This
translated to 0.86 bronchoscopies per stentmonth (a bronchoscopy every 1.2 mo). Twentysix subjects (14%) died during the initial stenting
period.

FIGURE 1. Flow diagram summarizing subject selection and outcomes. PITS indicates postintubation tracheal stenosis;
PTTS, post-tracheostomy tracheal stenosis.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
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TABLE 1. Delayed Stent-associated Complications and Secondary Bronchoscopic Management Burden Among 181
Subjects With at Least 6 Months Follow-up Available After Initial Stenting

Complication

Incidence, n (%)

Granulation
Migration
Mucostasis
Malfunction†
Overall

71
62
51
14
125

Number of Nonprotocolized
Bronchoscopies* Required
for Management, Per Patient

Median Time to First Event,
Weeks (Interquartile Range)

(39.2)
(34.3)
(28.2)
(7.7)
(69.1)

4.5
4
3.5
4
4

(10)
(6)
(7)
(12)
(5)

1.6
1.7
1.4
1.4
2.5

*Bronchoscopies performed in addition to those of the 1-month and 3-month stent surveillance protocol.
†Stent tear or malfolding.

subjects (36%) had their stents removed
because of intolerance before reaching planned
protocolized indwelling duration goal. The
most common single motive for premature
stent removal was recurrent stent migration

Ultimately, 149 subjects underwent stent
removal, with 128 available for analysis of
the primary outcome. Their characteristics
are shown in Table 2. Mean indwelling stent
duration was 25.2 weeks ( ± 21.1). Forty-six

TABLE 2. Characteristics of Subjects With and Without Restenosis at 1-year After Stent Removal
Patient Characteristics

Age at diagnosis, years, mean (SD)
Female
Diagnosis
PITS
PTTS
Hospitalized at time of diagnosis
Respiratory failure at time of diagnosis
Comorbid conditions
Hypertension
Diabetes
Morbid obesity
Gastroesophageal reﬂux disease
Chronic lung disease
Coronary disease
Chronic renal disease
Dependent functional status
Lesion and procedure characteristics
Proximal tracheal location
Cotton-Myer ≥ 3 obstruction
Length > 2 cm
Pseudoglottic (“A-shape”) conﬁguration
Associated malacia
Previous airway intervention
LAMD+mucosal therapy at time of initial stent
placement*
Initial stent type = silicone Y
Stent therapy characteristics
6-month stent protocol group (vs. 4-month)
Total indwelling stent time, weeks, mean (SD)
Revision of ﬁrst stent for any complication
Number of bronchoscopies† required to manage
stent complications, per stent-month, mean (SD)
Stent removed per protocol

Overall
(n = 128), n (%)

Restenosis
(n = 74), n (%)

No Restenosis
(n = 54), n (%)

P

52.2 (15.8)
84 (65.6)

51.1 (15.4)
51 (68.9)

53.6 (16.3)
33 (61.1)

0.262
0.451

46
82
60
28

(35.9)
(64.1)
(46.9)
(21.9)

26
48
39
13

(35.1)
(64.9)
(52.7)
(17.6)

20
34
21
15

(37.0)
(63.0)
(38.9)
(27.8)

0.152
0.197

74
59
51
50
44
40
22
17

(57.8)
(46.1)
(39.8)
(39.1)
(34.4)
(31.2)
(17.2)
(13.3)

42
38
36
31
29
22
12
10

(56.8)
(51.4)
(48.7)
(41.9)
(39.2)
(29.7)
(16.2)
(13.5)

32
21
15
19
15
18
10
7

(59.3)
(38.9)
(27.8)
(35.2)
(27.8)
(33.3)
(18.5)
(13.0)

0.857
0.209
0.019
0.469
0.193
0.702
0.814
0.999

108
62
52
46
43
37
57

(84.4)
(48.4)
(40.6)
(35.9)
(33.6)
(28.9)
(44.5)

61
38
36
24
21
28
38

(82.4)
(51.4)
(48.6)
(32.4)
(28.4)
(38.4)
(51.4)

47
24
16
22
22
9
19

(87.0)
(44.4)
(29.6)
(40.7)
(40.7)
(17.0)
(34.5)

0.62
0.714
0.045
0.356
0.185
0.01
0.073

26 (20.3)
64
25.19
52
0.54

(50.0)
(21.1)
(40.6)
(0.97)

82 (64.1)

11 (14.9)
38
24.73
38
0.72

(51.4)
(23.1)
(51.4)
(1.12)

40 (54.1)

15 (27.8)
26
25.81
14
0.29

0.854

0.08

(48.2)
(18.2)
(25.9)
(0.64)

0.858
0.236
0.006
0.005

42 (77.8)

0.009

*Laser-assisted mechanical dilation with mucosal steroid or antiﬁbrotic therapy.
†In addition to those performed as part of stent surveillance protocol, as outlined in text.
PITS indicates postintubation tracheal stenosis; PTTS, post-tracheostomy tracheal stenosis.

4 | www.bronchology.com

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Copyright r 2022 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

J Bronchol Intervent Pulmonol



Volume 00, Number 00, ’’ 2022

Tracheal Restenosis Postairway Stenting

TABLE 3. Multivariate Analysis Determining Predictors of Restenosis at 1-year Poststent Removal
Variable

OR

2.50%

97.50%

P

Diabetes
Coronary disease
Renal disease
Gastroesophageal reﬂux disease
Lung disease
Morbid obesity
Previous airway intervention
Length of stenosis > 2 cm (vs. 2 cm or shorter)
Cotton-Myer ≥ grade 3 obstruction (vs. less severe)
Pseudoglottic (“A-shape”) conﬁguration (vs. all others)
6-month stent duration protocol group (vs. 4-month)
Silicone Y-stent (vs. others)
LAMD+mucosal therapy at time of initial stent placement*
Bronchoscopies required† to manage complications, per stent-month

3.10
0.50
0.87
1.30
1.72
3.13
2.53
2.61
1.28
0.45
1.12
0.19
0.48
2.13

1.04
0.16
0.27
0.52
0.66
1.20
0.89
0.92
0.52
0.14
0.46
0.06
0.16
1.12

9.24
1.53
2.80
3.26
4.47
8.17
7.19
7.36
3.16
1.41
2.69
0.62
1.37
4.03

0.042
0.223
0.810
0.571
0.263
0.020
0.081
0.07
0.593
0.172
0.808
0.006
0.168
0.021

*Laser-assisted mechanical dilation with mucosal steroid or antiﬁbrotic therapy.
†In addition to those performed as part of stent surveillance protocol, as outlined in text.
LAMD indicates LASER-assisted mechanical dilation; OR, odds ratio.

(12 subjects), which occurred exclusively with
straight silicone stents.
The overall tracheal restenosis rate at 1 year
was 58% (74 subjects) and occurred at a median
of 1 week after stent removal (interquartile
range = 0 to 4). Bivariate analysis identiﬁed multiple factors associated with restenosis (Table 2).
Twenty subjects with restenosis became surgically
operable and were treated with resection. The
remaining 54 subjects were managed with
either tracheostomy or various bronchoscopic
applications, such as dilation, mucosal therapies,
and/or re-stenting (Fig. 1). Restenosis risk was

similar between stenting duration protocol groups
(6 vs. 4 months, P = 0.86).
Multivariate analysis of patient, lesion, and
stent-related characteristics identiﬁed coexisting
diabetes and morbid obesity, as well as occurrence of stent-associated complications requiring
bronchoscopic management as independent predictors for restenosis (Table 3). While the placement of a silicone Y-stent had a protective effect
against eventual restenosis compared with other
stent types [odd ratio (OR = 0.19, 95% conﬁdence
interval (CI) = 0.06-0.62, P = 0.006], Y-stent
therapy was also associated with death during the

FIGURE 2. Survival probability during airway stenting: subjects with silicone Y-stents and all others; P = 0.008.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
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initial stenting period (OR = 3.58, 95% CI = 1.409.14, P = 0.008; Fig. 2).
DISCUSSION

To our knowledge, this is the largest analysis to
date assessing the outcome of patients with complex postintubation and tracheostomy-associated
tracheal stenosis treated with bronchoscopic airway
stenting. We found that restenosis at 1 year after
stent removal was common overall (58%), and in a
large majority of subjects (85%) occurred within
1 month. Adjusted analysis revealed restenosis was
more likely in those with diabetes and morbid
obesity. It also occurred more in subjects who had
experienced stent-associated complications requiring additional intervention.
Success of airway stenting may depend on
multiple factors affecting the healing process,
including patient comorbidities, lesional features,
and therapeutic approach. Our ﬁndings are consistent with the underlying pathogenesis of PITS/
PTTS, which results from mucosal injury, exuberant inﬂammation, and dysregulated tissue repair
and remodeling.14–16 Local ischemia triggers
expression of hypoxia-inducible factor-1α and its
various target growth factors, resulting in activation of myoﬁbroblasts, deposition of extracellular
matrix and scar formation.17 Diabetes is an established marker of microvascular disease and a
known predictor of poorer wound healing because
of compromised tissue blood ﬂow and oxygen
delivery. For example, diabetic PITS patients
treated surgically are at higher risk for anastomotic
complications.18–20 The diabetics in our cohort also
had a suboptimal outcome with stent therapy.
Aggressive glycemic control and lifestyle modiﬁcation is of utmost importance for these patients
during their stenting period to optimize candidacy
for potential future operability.
We found morbid obesity was also associated
with a higher likelihood for restenosis. While
morbid obesity often coexists with other chronic
medical conditions, such as diabetes, coronary
disease, and gastroesophageal reﬂux, after
adjusting for these variables it remained an
independent risk factor for eventual restenosis.
This may be because of the presence of confounders not factored into our model. However,
obesity also represents an independent marker of
compromised wound healing because of multiple
factors such as alterations in immunoregulation,
tissue repair mechanisms, resistance to oxidative
stress, and nutrient utilization.21 As with
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glycemic control, weight loss should be an integral component of the management of these
patients.
Other microvascular disease-equivalents, such
as coronary insufﬁciency and chronic renal failure,
may also inﬂuence likelihood for restenosis. Lim
et al6 reported higher success of stent removal in
PITS patients who did not have cardiovascular
disease (OR = 12.20, P = 0.036). In contrast, our
model did not predict restenosis in those with
cardiac or renal comorbidity, and other studies
have not reported on this association. This may be
because demonstrating coexistent cardiovascular
illness in study design is more difﬁcult than
establishing presence of diabetes. In addition,
patients with renal disease are relatively uncommon in patients with PITS, limiting the sample size
available for analysis. Within our study only 19%
of subjects had evidence of renal failure of any
stage, while 52% had diabetes. Therefore, the
impact of cardiac or renal disorders on tracheal
restenosis after stent therapy remains unclear.
Our analysis did not reveal any lesional
characteristics to be convincingly predictive of
restenosis. Complex injuries of longer length
theoretically may represent a poorer template for
successful healing because of more severe
inﬂammation, increased chance for multilevel
cartilaginous compromise, and a higher likelihood of bacterial colonization with stenting.
Lesional length (and by extension, length of
resected trachea) is a recognized predictor for
poorer outcome after tracheal reconstruction.20
However, in our study the adjusted association of
longitudinal extent with restenosis after stent
removal approached, but did not reach, statistical signiﬁcance. Similarly, other investigations
of complex PITS patients treated with stenting
have not shown such an association.6,9,10 We also
found restenosis occurred with similar frequency
in PITS and PTTS subjects. That these and other
features such as severity of intraluminal compromise, location, conﬁguration, or associated
malacia failed to predict restenosis underscores
the complexity and heterogeneity of the disease.
Furthermore, detailing these characteristics during bronchoscopic evaluation remains subjective
and proceduralist dependent. Therefore, given
the data available, we caution against using
lesion-associated features to forecast potential
outcomes of stent therapy.
Among factors associated with stent therapy,
we found that subjects who had frequent stentrelated complications requiring bronchoscopic
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intervention were more likely to have restenosis.
Of these complications, stent migration likely
contributed most to eventual stent therapy failure. Migration occurred in 34% of our cohort,
and its recurrence was the most frequent reason
for stent revisions and premature stent removal.
Not surprisingly, these patients had a signiﬁcantly higher risk of restenosis than those who
tolerated their stents until the target protocolized
removal date (74% vs. 49%, P = 0.009). A consistently stable airway during stent therapy is
likely an important factor in promoting healing.
Recurrent migrations lead to lesion re-exposure,
potential reinjury because of additional intervention, and a resetting of remodeling. Supporting this theory is that in our cohort migration did
not occur with Y-stents, and the use of a Y-stent
protected against restenosis even though these
patients still required interventions to manage
other complications. The “stable” Y-stent may
have optimized chances for healing by more
consistently protecting the lesion and minimizing
recurrent local insult. Unfortunately, predicting
which straight stent types are more likely
to migrate is challenging. To our knowledge,
other studies have not adequately evaluated the
impact of stent-associated complications on stent
therapy outcomes in this patient population.
While a reasonable conclusion then could be
to manage these patients preferentially with
Y-stents, we also found Y-stent therapy to be
associated with death during the stenting period.
This was after adjusting for multiple variables
including comorbidities, stenosis length, severity
of luminal obstruction, and need for bronchoscopic interventions. This result, which negated
the beneﬁt on restenosis rate, has several potential explanations. Y-stents for PITS/PTTS usually require a long tracheal limb to ensure proper
coverage of proximally located lesions. This
substantially reduces the surface area of otherwise normal trachea and can increase the risk for
tenacious mucostasis and secondary airway
obstruction or respiratory infection. Indeed,
when reviewing the proﬁle of deceased subjects in
our cohort, 16 of 26 (62%) died either as a direct
result of or in association with a respiratory issue.
Eleven of these subjects (69%) had Y-stents in
place at time of death. Furthermore, the relatively ﬁxed proximal aspect of the Y-stent in the
subglottis can hinder endotracheal intubation,
especially in an emergent or uncontrolled situation. At least 3 deaths in our cohort were
preceded by a difﬁcult intubation, all in subjects

Tracheal Restenosis Postairway Stenting

with Y-stents. Reasons for utilizing a Y-stent for
a particular PITS/PTTS patient include presence
of long segment, mixed, and/or distal tracheal
disease, extensive airway malacia, high chance
for straight stent migration, or failed straight
stent therapy. On the basis of our ﬁndings,
Y-stents should be carefully chosen and reserved
for patients who understand associated risks, are
able to strictly comply with stent clearance
techniques, and have ready access to appropriate
medical care.
While such stent-related risks emphasize the
importance of minimizing stenting duration as
much as possible in patients with PITS/PTTS, the
inﬂuence of indwelling stent time on eventual
therapeutic success remains unclear. Several
experts advocate for a prolonged stenting period,
up to 18 to 24 months or more.7,22,23 This intuitively makes sense, as a longer stenting duration
may maximize chances for airway remodeling
and healing. However, the available literature
provides heterogeneous and inconsistent results
from a fairly small sample size, limiting conclusions. For example, in one of the larger
reports available, restenosis occurred in 18 of 81
subjects (22%) with PITS or PTTS treated with
stenting for a minimum of 52 weeks.9 In contrast,
in a separate study, restenosis was seen in 33 of
55 subjects (60%) with complex PITS after silicone stenting for a similar time period.6 This
latter restenosis rate is nearly identical to our
ﬁndings, but indwelling stent time in our cohort
was substantially shorter, at 25 weeks. Other
studies report restenosis risk ranging from 0% to
70% with indwelling stent times between 24 and
128 weeks.2–9 However, these are of smaller
samples and with inconsistently reported criteria
for stent removal (Table 4). We did not ﬁnd
stenting duration predicted restenosis. Nevertheless, it remains unclear whether longer or even
indeﬁnite stent therapy is needed in patients with
the risk factors for restenosis identiﬁed in our
analysis, and further investigation is needed.
The main limitation of our study is its retrospective and single institution design, though the
analysis was conducted on a large, prospectively
maintained database. Twenty of the 149 subjects
who had their stents eventually removed were lost
to follow-up before reaching the 1-year analysis
point, with their clinical outcome unknown. While
some of these individuals may have had restenosis
and sought therapy elsewhere, others may have
felt “cured” and decided to defer further clinical
care. Nevertheless, we consider the 87% follow-up
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TABLE 4. Selected Literature Review of Restenosis Risk After Stent Therapy for Complex Postintubation and
Tracheostomy-associated Tracheal Stenosis
Study

Brichet et al2
Puma et al7
Schmidt et al8
Galluccio et al5
Lim et al6
Terra et al10
Shin et al9
Freitas et al4
This study
Total

Criteria for Stent Removal

Operative candidacy at 6 mo
Epithelialization, adequate airway patency, lack of
malacia
Reduced inﬂammation, adequate airway patency
Individualized
Minimum 12-month indwelling time, stable airway
for 6 mo
Clinical stability, adequate airway patency, lack of
inﬂammation, bleeding, granulation, malacia
Stable airway for one year, presence of peristent air
Individualized; adequate airway patency
Stable airway for either 4 or 6 mo

Indwelling Stent Time
(Approx. weeks)

Restenosis/Total Stents
Removed (%)

At least 24
128

7/10 (70)
6/14 (43)

80
72
52

0/12 (0)
12/33 (36)
33/55 (60)

NR

2/21 (10)

At least 52
88
25
Median = 76*

18/81 (22)
7/14 (50)
74/128 (58)
159/368 (43)

*The median indwelling stent time calculation does not include data from references 2, 9, and 10.
NR indicates not reported.

rate in our cohort acceptable for reaching our
conclusions. Finally, our study should not be
interpreted as an analysis of long-term stent therapy success for complex PITS, since we chose
restenosis after ﬁrst stent removal as the primary
outcome. It is possible that such patients who
require re-stenting for a longer duration may have
their stents permanently removed at a later time or
be managed successfully with indeﬁnite stenting.
In summary, we provide a comprehensive
assessment of bronchoscopic airway stenting in
patients with complex PITS and PTTS. We highlight several potential risk factors for failure that
may be used to guide initial stent therapy and
outcome expectations. The management of these
patients remains problematic owing to an inadequately studied and heterogeneous population
that has many medical comorbidities, and should
be pursued within a multidisciplinary context.
Further investigation is needed to identify the
optimal approach.
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